HeartFlow unveils next generation FFRct Analysis

26 June 2016 (Last Updated June 26th, 2016 18:30)

US-based medical technology company HeartFlow has introduced the next generation of the HeartFlow FFRct Analysis.

US-based medical technology company HeartFlow has introduced the next generation of the HeartFlow FFRct Analysis.

The next generation platform has undergone modifications on process and algorithms which is used by HeartFlow to calculate FFRct values.

HeartFlow chairman and CEO John Stevens said: "This is a major milestone for HeartFlow and a crucial advancement as we see increasing adoption of the HeartFlow Analysis around the world.

"The platform is now characterised with more security measures to cater to the requirement of healthcare institutions across the world."

"With this next generation platform, HeartFlow will be able to deliver results more quickly and securely to the growing number of physicians using the HeartFlow Analysis to aid in the diagnosis of coronary artery disease."

An enhanced new Heartflow platform features advanced algorithms and streamlined case processing which enables a faster generation of HeartFlow Analysis results to clinicians.

Multiple layers of nonlinear algorithms are integrated by deep learning which assists in determining patterns and thereby improving understanding of the information.

The cloud-based infrastructure of the platform uses Amazon Web Services (AWS) to ensure a secure, robust and scalable delivery of the HeartFlow service.

The platform is now characterised with more security measures to cater to the requirement of healthcare institutions across the world.

HeartFlow co-founder and chief technology officer Charles Taylor said: "One of the benefits of HeartFlow's cloud-based platform is that the technology utilises the data we receive from our global community of clinicians."

The HeartFlow Analysis is a non-invasive technology which offers an insight into both the extent of coronary artery disease and the impact of disease on blood flow to the heart, enabling clinicians to select an appropriate treatment.